Pharmacodynamic evaluation for antiplasmodial activity of *Holarrhena antidysentrica* (Kutaja) and *Azadirachta indica* (Neemb) in *Plasmodium berghei* infected mice model

Jadhav Priyanka¹*, Lal Hingorani², Kshirsagar Nilima³

¹University Department of Infectious Diseases and University Department of Interpathy Research and Technology, Maharashtra University of Health Sciences, Mumbai, India
²Pharmanza Herbals Pvt. Ltd., Mumbai, India
³Office of National Chair (Clinical Pharmacology), Indian Council of Medical Research (ICMR), Government of India. Dean ESI–PGIMSR MGM Hospital, Govt. of India, Mumbai, India

**ARTICLE INFO**

**ABSTRACT**

**Objective:** To investigate in-vivo anti-plasmodial activity of aqueous extracts of plants selected based on the symptomology mentioned in Ayurveda. **Methods:** The aqueous extracts of *Holarrhena antidysentrica* (*H. antidysentrica*) (Kutaja) and *Azadirachta indica* (*A. indica*) (Neemb) for their antiplasmodial potential in *Plasmodium berghei* (*P. berghei*) infected mice was assessed using Peters four day suppressive test. Both the extracts were administered at 2 dose levels, full dose (1 000 mg/d) and minimized dose (200 mg/d). 10⁶ *P. berghei* infected RBCs were injected on day ‘0’ and treated from day ‘0’ till day ‘3’ post–infection. Tail blood smears were collected, giemsa stained and analyzed. The mice were observed for survival and parasitemia was assessed till 50% of mice in control survived. **Results:** It was observed that the percentage of parasitemia increased gradually in all the groups, with maximum in control group (Day 3-35, Day 9-46.98) and minimum in Chloroquine arm (Day 3-14.06, Day 9-19.92). The percentage of parasitemia was compared using Mann–Whitney *U* test depicting that all test groups exhibited reduction in parasitemia as compared to control (*P*-value<0.002 for all groups). These groups showed similar percentage of survival as Chloroquine. **Conclusions:** The present investigation demonstrated the anti-plasmodial effects of *H. antidysentrica* and *A. indica*, which are two most commonly used medicinal plants in Ayurved for treatment of fever.

1. **Introduction**

Malaria is a major health problem in India and contributes significantly to the overall malaria burden in Southeast Asia. The National Vector Borne Disease Control Program of India reported ~1.6 million cases and ~1 100 malaria deaths in 2009. Some experts argue that this is a serious underestimation and that the actual number of malaria cases per year is likely between 9 and 50 times greater, with an approximate 13–fold underestimation of malaria–related mortality[1,2]. Complexities in the life cycle of parasite, environmental interactions, high cost of anti–malarial drugs for people living in endemic countries, migration of population between endemic and non–endemic areas and resistance of *Plasmodium falciparum* (*P. falciparum*) to chloroquine, mefloquine and sulfadoxine–pyrimethamine including artemisinin combined therapies, has fuelled the burden of this protozoal infection further more[3–6]. Ever–increasing resistance of malarial parasites to the
commonly available anti-malarial drugs necessitated the search for new drugs, especially from plants. Traditionally used medicinal plants have played important role in malaria treatment across the globe [7-9]. We investigated the plants selected on the basis of their traditional usage by comparing the disease symptomatology and recommended use from the texts of Ayurveda (Indian System of Medicine) and used them in the forms as used traditionally (water extracts and herb powders) as far as possible. We screened aqueous extracts of two plants *Holarrhena antidysenterica* (*H. antidysenterica*) (Kutaja) and *Azadirachta indica* (*A. indica*) (Neemb) for their antiplasmodial potential in *Plasmodium berghei* (*P. berghei*) infected mice.

**2. Materials and methods**

**2.1. Plant materials**

The plants selected viz. *A. indica* (leaves, stem) and *H. antidysenterica* (bark) were collected from Gujarat state of India. The plant species were taxonomically identified and confirmed using morphological and anatomical technique. They were authenticated at the Botanical Survey of India, Pune and voucher specimens were deposited.

**2.2. Preparation of samples**

Aqueous extracts were prepared from 500 g of fresh raw material of plant parts in a round bottom flask. This mixture was heated in stainless steel extraction vessel under reflux with stirrer for three cycles with water. After each cycle, water was added to replenish the remaining volume. The extracts were dried in a rotatory evaporator under vacuum at temperature not exceeding 35 °C. The dry extracts of all samples were stored in air-tight sample containers at 4 °C until use. For administration to the animals, the aqueous extracts were diluted in distilled water and vortex to get a clear solution.

**2.3. Pharmacodynamic evaluation: in vivo antimalarial efficacy testing in *P. berghei* infected mice**

The protocol for animal studies was approved by the Institutional ethical committee of the Tata Institute of Fundamental Research, (TIFR). The protocol was designed on the basis of "Peters four day suppressive test" described by Peters *et al.* [10,11]. The lethal strain of *P. berghei* was used for the experiments. In-house bred mycoplasma free male Swiss mice (weighing around 30 g each) were infected by intraperitoneal inoculation of donor mouse blood diluted in acid citrate dextrose (ACD) buffer containing approximately $10^8$ *P. berghei* infected RBCs on day '0'. The mice were randomly divided into various groups (*n=8* per group) as depicted in Table 1. Starting from day '0' till day '3' post infection, the different groups were given the assigned treatment (or no treatment for control) by oral gavage. The total volume administered was 400 µL. On fourth day, the blood was withdrawn from tail vein and the blood smears were prepared. Blood smears were fixed with methanol and stained with Giemsa stain and the parasites were counted. Parasitemia is the quantitative content of parasites in the blood. Parasitemia was reported as percentage parasitemia after counting 250 RBCs from each slide. Activity of the treatment groups was calculated by the following formula suggested in the standard protocol by Fidock *et al.*[12].

Activity = 100–(mean parasitemia of treated group/mean parasitemia of control group) × 100

The animals in all the groups were also monitored for their survival.

**Table 1**

Summary of the different groups and their treatment regimen used for *in vivo* antimalarial efficacy studies.

| Group (*n=8*) | Infection Treatment |
|--------------|---------------------|
| Full dose of *H. antidysenterica* (HA) | 1,000 mg/d of *H. antidysenterica* |
| Minimized dose of *H. antidysenterica* (HA) | 200 mg/d of *H. antidysenterica* |
| Full dose of *A. indica* (AI) | 1,000 mg/d of *A. indica* |
| Minimized dose of *A. indica* (AI) | 200 mg/d of *A. indica* |
| Chloroquine | 5 mg/kg/d of Chloroquine |
| Control | No treatment |

**2.4. Statistical analysis**

Data was expressed as mean±SD. and parasitemia of the different groups were statistically assessed by unpaired *t*-test using Graphpad Instat Demo version. Differences were considered significant at *P*<0.05.

1. % Parasitemia of infected mice was calculated:

\[
\text{% Parasitemia} = \frac{\text{Number of infected red blood cell}}{\text{Total red blood cell}} \times 100 = \% \text{ parasitemia}
\]

2. % Activity of the treatment groups was calculated by the following formula suggested in the standard protocol by Fidock *et al.*[12]
% Activity = 100–mean parasitemia of treated group/mean parasitemia of control group × 100

3. Percent suppression of parasitemia was calculated:
Parasitemia of control–parasitemia of test/ Parasitemia of control × 100

4. Number of survival days and % survival was calculated.

3. Results

The % parasitemia was calculated till 50% of animals in control survived, which was Day 9. The mean % parasitemia of the mice in each group was as mentioned in Table 2. It was observed that the % parasitemia increased gradually in all the groups, with maximum in control group (Day 3−35, Day 9−46.98) and minimum in Chloroquine arm (Day 3−14.06, Day 9−19.92) (Figure 1).

Table 2
The mean % parasitemia seen in each group was as follows.

| Group          | Day 3      | Day 4      | Day 5      | Day 6      | Day 7      | Day 9      |
|----------------|------------|------------|------------|------------|------------|------------|
| Full dose of H. antidysenterica | 19.58      | 20.69      | 26.41      | 31.68      | 32.29      | 33.10      |
| Minimized dose of H. antidysenterica | 15.54      | 16.16      | 16.44      | 19.23      | 19.58      | 20.38      |
| Full dose of A. indica | 16.10      | 16.91      | 23.73      | 25.87      | 25.65      | 26.35      |
| Minimized dose of A. indica | 16.55      | 17.17      | 21.69      | 24.31      | 24.52      | 25.20      |
| Chloroquine     | 14.06      | 16.22      | 17.12      | 18.04      | 18.65      | 19.92      |
| Control         | 35.00      | 36.31      | 37.90      | 45.46      | 46.26      | 46.98      |

Figure 1. % parasitemia in the groups from day 3 to day 9.

The % parasitemia was compared using Mann–Whitney U test depicting that all test groups exhibited reduction in parasitemia as compared to control (P-value<0.002 for all groups). While it was observed that the reduction in H. antidysenterica minimized dose group and A. indica group was comparable to Chloroquine (Figure 2).

It was assessed using Mann–Whitney U test, the parasitemia reduction in H. antidysenterica minimized dose group and A. indica group was comparable to Chloroquine. While all the test groups showed statistically significant reduction as compared to distilled water (P value < 0.002 for all groups).

% activity was calculated using the formula as mentioned above (Figure 3). It was observed that minimized dose HA showed comparable activity to Chloroquine. Percent suppression in these 2 groups was similar too. In both these groups 3 animals survived till Day 10, while % survival was highest in minimized dose HA amongst the test groups followed by minimized dose AI, and full dose AI (Table 3 and 4).

Table 3
| Treatment group | Average %parasitemia±SD | %activity | No. of survivals |
|-----------------|-------------------------|-----------|-----------------|
|                 | 3rd day | 9th day | 3rd day | 9th day |
| HA full        | 19.6±2.8 | 33.1±4.8 | 44 | 30 | 0 |
| Minimized dose of H. antidysenterica | 15.5±4.1 | 20.4±3.3 | 56 | 57 | 3 |
| Chloroquine     | 14.1±3.3 | 19.9±2.3 | 60 | 58 | 3 |
| Control         | 35.0±4.7 | 47.0±9.6 | 0 | 0 | 0 |

Figure 2. % parasitemia.
Table 4

| Plant extract       | Dose      | Mean ± SD | Percent parasitemia suppression of animal (%) | % Survival of parasitemia day 10 |
|---------------------|-----------|-----------|---------------------------------------------|---------------------------------|
| H. antidysentrica   | 1000 mg/d | 27.3 ± 6.0| 34                                          | 13                              |
| H. antidysentrica   | 200 mg/d  | 17.9 ± 2.1| 57                                          | 63                              |
| A. indica           | 1000 mg/d | 22.4 ± 4.7| 46                                          | 38                              |
| A. indica           | 200 mg/d  | 21.6 ± 3.8| 48                                          | 50                              |
| Chloroquine         | 5 mg/kg/d | 17.3 ± 2.0| 58                                          | 100                             |
| Distilled water     | –         | 41.3 ± 5.5| –                                            | –                               |

Figure 3. % activity in all the treatment groups compared to the controls.

The survival analysis was performed using ANOVA to compare the 2 dose levels of drugs with chloroquine and control group. Low dose was found to be more efficacious than full dose of test sample, when compared with control ($P$-value <0.001) (Figure 4).

Figure 4. Survival proportions of all the groups.

4. Discussion

In this study, we have found that the both aqueous extracts of H. antidysentrica and A. indica demonstrated the anti-plasmodial property. The parasitemia was reduced in both the dose ranges for these extracts as compared to control ($P$ value <0.002). Although H. antidysentrica minimized dose and A. indica group were comparable to Chloroquine for lowering parasitemia and for survival. A. indica minimized dose showed slightly better percent suppression of parasitemia and % survival than its full dose. The present investigation thus demonstrated the anti-plasmodial effects of H. antidysentrica and A. indica which are two most commonly used medicinal plants in Ayurved for treatment of fever.

The interest in screening of compounds of natural origin or of ethno pharmacological background to develop antimalarial therapy has increased in last few years. Many plants compounds and extracts used traditionally have exhibited promising anti-plasmodial activity. In present study we used 1000 mg/d and 200 mg/d dose calculated for weight of mice. We used aqueous extracts and water as a solvent to mimic the traditional use of these plant compounds. Percent parasitemia of infected mice and percent activity of the treatment groups were calculated as per the formula mentioned by Fidock et al[12]. Percent suppression of parasitemia was assessed using the formula by Obih et al[14]. Statistical significant reduction in percent parasitemia of all the test groups was found when compared with the control using Mann Whitney U test ($P$ value <0.002). The reduction was comparable to Chloroquine group for H.antidysentrica minimized dose group and A. indica full dose. The numbers of survival till day 18 were observed in H. antidysentrica minimized dose group, A. indica full and minimized dose group and Chloroquine indicating the effect of treatment groups on the survival of infected mice. H. antidysentrica minimized dose exhibited 57% suppression of parasitemia followed by A. indica minimized dose (48%) and A. indica full dose (46%) in the treatment groups. The survival was 63% in H. antidysentrica minimized dose followed by the A. indica minimized dose (50%). It can be noted that both the minimized doses exhibited better parasitemia suppression and survival as compared to full dose. Recently a study published by Verma et al screened the 10, 20 & 30 mg/kg of chloroform extract of the H. antidysentrica in P. berghei infected mice, which demonstrated 73.2% parasite inhibition at 30 mg/kg[15]. There are very few studies for H. antidysentrica including the one mentioned above published recently. A. indica fractions have shown activities superior to chloroquine in-vitro[16,17]. Yet there were very few studies with aqueous extracts of A. indica and its activity in a mouse model. Many other Indian medicinal plants have been examined in–vitro against P. falciparum, of which ethanol extracts Holarrhena pubescens, Pongamia pinnata, Plumbago zeylanica have exhibited IC$_{50}$ of 28 μg/mL, 25 μg/mL and 17 μg/mL[18]. The IC$_{50}$ of various solvent extracts of Carica papaya, Ocimum sanctum, Adhatoda vasica, etc indicated anti-plasmodial activity of the traditionally used
medicinal plants\textsuperscript{[19]}. Ellagic acid which is an important chemical constituent of \textit{Punica granatum}, exhibited high \textit{in-vitro} and \textit{in-vivo} antiplasmodial properties and synergistic activity with chloroquine, atovaquone, melofloune and artesunate\textsuperscript{[20]}.

Other traditional medicinal plants from Kenya have also shown low IC\textsubscript{50} values, high percent suppression and low cytotoxicity, thus indicating potential source for anti-plasmodial agents\textsuperscript{[21]}. \textit{A. indica} along with other Sudanese medicinal plants exhibited highly potent antimalarial property\textsuperscript{[22]}. Thus it is evident that traditionally used medicinal plants have potential and must be explored for novel drug candidate.

**Conflict of interest statement**

We declare that we have no conflict of interest.

**References**

[1] Das A, Anvikar AR, Cator LJ, Dhiman RC, Eapen A, Mishra N, et al. Malaria in India: The center for the study of complex malaria in India. Acta Trop 2012; 121(3): 267–273.

[2] Tsabang N, Fokou PV, Tchokouaha LR, Noguem B, Bakarnga-Via I, Nguepi MS, et al. Ethnopharmacological survey of \textit{Annonaceae} medicinal plants used to treat malaria in four areas of Cameroon. J Ethnopharmacol 2012; 139(1): 171–180.

[3] Vargas S, Ndjoko Ioset K, Hay AE, Ioset JR, Wittlin S, Hostettmann K. Screening medicinal plants for the detection of novel antimalarial products applying the inhibition of beta-hematin formation. J Pharm Biomed Anal 2011; 56(5): 880–886.

[4] Marsh K. Malaria disaster in Africa. Lancet 1998; 352(9132): 924.

[5] White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113(8): 1084–1092.

[6] Roy SB, Sarkar RR, Sinha S. Theoretical investigation of malaria prevalence in two Indian cities using the response surface method. Malar J 2011; 10: 301.

[7] Mesfin A, Giday M, Animut A, Teklehaymanot T. Ethnobotanical study of antimalarial plants in Shingle District, Somali Region, Ethiopia, and \textit{in vivo} screening of selected ones against \textit{Plasmodium berghei}. J Ethnopharmacol 2012; 139(1): 221–227.

[8] Gathiirwa JW, Rukunga GM, Mwitiar PG, Mwikwabe NM, Kimani CW, Muthaura CN, et al. Traditional herbal antimalarial therapy in Kilifi district, Kenya. J Ethnopharmacol 2011; 134(2): 434–442.

[9] Kamaraj C, Kaushik NK, Mohanakrishnan D, Elango G, Bagavan A, Zahir AA, et al. Antiplasmodial potential of medicinal plant extracts from Malaiyur and Javadhu hills of South India. Parasitol Res 2012; 111(2): 703–715.

[10] Peters W, Davies EE, Robinson BL. The chemotherapy of rodent malaria. \textit{X}\textsuperscript{t}: Causal prophylaxis, part \textit{X}: Practical experience with \textit{Plasmodium yoelii} nigeriensis in drug screening. Ann Trop Med Parasitol 1975; 69(3): 311–328.

[11] Peters W. The chemotherapy of rodent malaria, \textit{X}\textsuperscript{t}: The value of drug–resistant strains of \textit{P. berghei} in screening for blood schizontocidal activity. Ann Trop Med Parasitol 1975; 69(2): 155–171.

[12] Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 2004; 3(6): 509–520.

[13] Muregi FW, Ishih A, Miyase T, Suzuki T, Kino H, Amano T, et al. Antimalarial activity of methanolic extracts from plants used in Kenyan ethnomedicine and their interactions with chloroquine (CQ) against a CQ–tolerant rodent parasite, in mice. J Ethnopharmacol 2007; 111(1): 190–195.

[14] Ohl P, Makinde M, Laoye OJ. Investigations of various extracts of \textit{Morinda lucida} for antimalarial actions on \textit{Plasmodium berghei} \textit{berghei} in mice. Afr J Med Sci 1985; 14(1–2): 45–49.

[15] Yemna G, Dua VK, Agarwal DD, Atul PK. Anti–malarial activity of \textit{Holarrhena antidentserica} and \textit{Viola canescens}, plants traditionally used against malaria in the Garhwal region of northwest Himalaya. Malar J 2011; 10: 20.

[16] Udeinya IJ, Brown N, Shu EN, Udeinya FI, Quakyeje I. Fractions of an antimalarial neem–leaf extract have activities superior to chloroquine, and are gametocytocidal. \textit{Ann Trop Med Parasitol} 2006; 100(1): 17–22.

[17] Alshawsh MA, Mothana RA, Al–Shamahy HA, Alslami SF, Lindequist U. Assessment of antimalarial activity against \textit{Plasmodium falciparum} and phytochemical screening of some Yemeni medicinal plants. \textit{Exid Based Complement Alternat Med} 2009; 6(4): 453–456.

[18] Simonson HT, Nordskjold JB, Smitt UW, Nyman U, Palpu P, Joshi P, et al. \textit{In vitro} screening of Indian medicinal plants for antiplasmodial activity. J Ethnopharmacol 2001; 74(2): 195–204.

[19] Venkatesalu V, Gopalan N, Pillai CR, Singh V, Chandrasekar M, Thilakumar A, et al. \textit{In vitro} anti–plasmodial activity of some traditionally used medicinal plants against \textit{Plasmodium falciparum}. Parasitol Res 2012; 111(1): 497–501.

[20] Soh PN, Witkowski B, Olagnier D, Nicolau ML, Garcia-Alvarez MC, Berry A, et al. \textit{In vitro} and \textit{in vivo} properties of ellagic acid in malaria treatment. \textit{Antimicrob Agents Chemother} 2009; 53(3): 1100–1106.

[21] Gathiirwa JW, Rukunga GM, Mwikwabe NM, Kimani CW, Muthaura CN, et al. Traditional herbal antimalarial therapy in Kilifi district, Kenya. J Ethnopharmacol 2011; 134(2): 434–442.

[22] El–Tahir A, Satti GM, Khalid SA. Antiplasmodial activity of selected Sudanese medicinal plants with emphasis on \textit{Acacia nilotica}. \textit{Phytother Res} 1999; 13(6): 474–478.